majestec-2 trial | emma searle, mbchb ma mrcp frcpath phd | ash 2022
Published 1 year ago • 260 plays • Length 5:39Download video MP4
Download video MP3
Similar videos
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
1:31
quad therapies and side effects | nathan sweeney, phd | ash 2022
-
4:19
optimum muk nine trial | martin kaiser, md | ash 2022
-
2:10
new developments at ash | rafat abonour, md | ash 2022
-
5:22
individualized prediction model in myeloma & genome sequencing | francesco maura, md | ash 2022
-
1:00:53
how fast can multiple myeloma progress and what biologically happens when it does?
-
10:20
understanding multiple myeloma (multiple myeloma explained clearly)
-
9:37
what are the stages of multiple myeloma?
-
5:29
updates on teclistamab, talquetamab, and carvykti | mark wildgust, phd | ash 2022
-
4:08
frailty and multiple myeloma | hira mian, md, msc | ash 2022
-
2:47
results from the optimum/muknine trial | martin kaiser, md, frcp, frcpath | ash 2023
-
1:15
patient top concerns at and since diagnosis | nathan sweeney, phd | ash 2022
-
2:27
mrd detection in blood | bruno paiva, phd | ash 2022
-
9:33
talquetamab | ajai chari, md | ash 2022
-
1:38
what to look forward to at ash | ola landgren, md, phd | ash 2022
-
2:00
advancements in immunotherapy agents | hearn j. cho, md | ash 2022
-
1:44
post bcma therapy | gurbakhash kaur, md | ash 2022
-
3:44
bispecific t cell engagers | noopur raje, md | ash 2022
-
2:57
modakafusp alfa (tak-573) | dan vogl, md, msce | ash 2022
-
3:19
revlimid refractory patients in daratumumab clinical trials | binod dhakal, md | ash 2022
-
1:23
outcomes of triple class refractory multiple myeloma patients | james berenson, md | ash 2023